Efficacy of Home-delivered Transcranial Direct Current Stimulation (tDCS) of the Motor Cortex in Patients With Chronic Pain Transiently Relieved by Motor Cortex rTMS : a Pragmatic Randomized Double Blind Sham Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Self reported pain intensity in a diary
研究概览
简要总结
This clinical investigation aims to evaluate the efficacy and safety of a home-based device providing electrical stimulation of the brain named transcranial direct current stimulation (tDCS ) , in patients with chronic pain who have been transiently relieved by repetitive transcranial magnetic stimulation delivered at hospital (less than one month benefit). The general objective is to show that these patients may best benefit from home based tDCS while rTMS performed in hospital has only limited and transient efficacy. Each participant will be randomized into one of two arms to receive during 3 months either active tDCS or sham tDCS. Neither the investigator nor the patient will be aware of the treatment. The efficacy will be assessed on pain intensity (primary outcome at 3 months) and several secondary outcomes (qualify of life, pain symptoms , global impression of change, pain relief, sleep, anxiety, depression) every month for up to 3 months. Safety will be assessed at each follow up visit for up to 3 months. The participants will be asked to self stimulate themselves with the device 5 days per week for about 20 minutes.
详细描述
This will be a randomised, double-blind, parallel-group, bi-centric study versus placebo stimulation. Patients undergoing previous treatment with rTMS of the motor cortex in routine in our pain center and with at least 30 % pain relief with rTMS (after 10 sessions) but only transient pain relief (less than one month) will stop their treatment for at least one month. They will then be randomised to receive one of the 2 treatments under study (active tDCS of the motor cortex, placebo tDCS of the motor cortex, TENS eco plus). The protocol will involve a 20-minute tDCS session (2 mA) at home, 5 days a week for 12 weeks. The treatment will continue for 12 weeks and the final evaluation will take place at 12 weeks.
TENS ECO PLUS is a portable transcranial direct current stimulation (tDCS) system (tDCS kit) supplied by the Monath Electronic laboratory, designed for use at home; this system will first be tested in hospital during a test session with explanations to the patient on how to use it. The stimulation intensity is blocked above a certain threshold by the system to avoid any risk of epileptic seizure. Sham or placebo stimulation uses the same medical device without active stimulation.
Given the exploratory nature of the trial and in order to reduce study participant's exposure to a potentially useless treatment, blinded interim analysis will be conducted dring the course of the trial in the first 40 enrolled patients and the study will be stopped early if this analysis suggests large differences between the two treatment groups or conversely shows obvious futility.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic pain for at least 6 months Pain intensity ≥ 4/10 on 0-10 NRS Pain present every day or nearly every day Neuropathic pain (DN4 score ≥ 4/10) or nociplastic pain (Kosek et al Pain 2021) Patients previously treated with rTMS of the motor cortex in routine in our pain center but with only transient efficacy (ie, efficacy for less than one month, defined as pain intensity improved by at least 30 %) Affilitated to social security
排除标准
- •Contraindications to tDCS as stated in the manufacturer brochure (ie, implantable device , severe cognitive disorders, epilepsia, skin problems where will placed the electrodes, arterial or venous thrombosis, thrombophlebitis, metallic intracranial implant, cranioth-omy, incracranial aneuvrysm, cerebral tumor, severel sleep disorders such as narcolepsia) Conciomitant treatment which might increase the risk of epilepsia such as high doses opioids (≥ 140 mg morphine equivalent) or high. doses tricyclic antidepressants (≥ 150 mg per day) Pregnancy or lactation Age below 18 or > 80 years Pending litigation related to pain Pain more severe than neuropathic or nociplastic pain requiring treatment Severe disease such as cancer Severe psychiatric condition (psychosis) Impossible to be followed for up to 3 months Participation in a recent protocol (less than 3 months) Psychoactive drug abuse
研究组 & 干预措施
Active tDCS
Active tDCS of the motor cortex
干预措施: tDCS of the motor cortex (Device)
Sham tDCS
Sham tDCS of the motor cortex
干预措施: tDCS of the motor cortex (Device)
结局指标
主要结局
Self reported pain intensity in a diary
时间窗: Baseline and 12 weeks
Weekly average of the last 7 numerical pain scores (from 0 no pain to 10 maximal pain imaginable) recorded every day by the patient at the end of the treatment as compared to baseline values
次要结局
- Effects on self reported pain intensity over the course of the study(over the course of the study from baseline to week 12)
- EQ-5D-5L (EuroQol)(Baseline, then week 1 (± 3 days), week 4, week 8 and week 12)
- Brief Pain Inventory(Baseline, then week 1 (± 3 days), week 4, week 8 and week 12)
- Neuropathic Pain Symptom Inventory (NPSI)(Baseline, then week 1, week 4, week 8 and week 12 after the treatment)
- Fibromyalgia Impact Questionnaire (FIQ)(Baseline, then week 1 (± 3 days), week 4, week 8 and week 12)
- Hospital anxiety and depression scale (HADS)(Baseline, then week 1 (± 3 days), week 4, week 8 and week 12)
- Medical outcomes study sleep scale (MOS sleep)(Baseline, then week 1 (± 3 days), week 4, week 8 and week 12)
- McGill pain questionnaire short form (SF-MPQ)(Baseline, then week 1 (± 3 days), week 4, week 8 and week 12)
- Pain Catastrophizing Scale (PCS)(Baseline then 1 week ± 3 days then 4 weeks, 8 weeks and 12 weeks)
- Patient global impression of change (PGIC)(Baseline then 4 weeks, 8 weeks and 12 weeks)
- Treatment-emergent adverse effects of home delivered tDCS(Every day over the course of the study and at each follow up visit, at days 3 (initial follow up safety visit) then days 10, week 4, week 8 and week 12)
- Categorical pain scale(Baseline then 10 days (± 3 days), 4, 8 and 12 weeks)
- Blinding assessment(12 weeks)
- Satisfaction with the treatment(12 weeks)
- Interference score of the Brief Pain Inventory(Baseline then 1 week, 4 weeks, 8 weeks and 12 weeks after the treatment)
- Pain as its least from the Brief Pain Inventory(Baseline then 1 week, 4 weeks, 8 weeks and 12 weeks after the treatment)
- Pain as its worst from the Brief Pain Inventory(Baseline then 1 week, 4 weeks, 8 weeks and 12 weeks)
- Clinician global impression of change (CGIC)(Baseline and at 12 weeks)
- EQ5D -5L Euroqol Visual analog scale(Baseline, week. 1, weeks 4, weeks 8 and weeks 12 after the treatment)
- Symptoms of depression on the Hospital Anxiety and Depression Scale (HADS)(Baseline then one week, 4 weeks, 8 weeks and 12 weeks)
- Short Form McGill Pain Questionnaire SF-MPQ(Baselinen one week, 4 weeks, 8 weeks and 12 weeks after the treatment)
研究者
Nadine ATTAL
Coordinator
Hospital Ambroise Paré Paris